Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Edotreotide→

Edotreotide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
204318-14-9
Molecular formula
C65H92N14O18S2
Molecular weight
1421.6 g/mol
Drug class
Somatostatin analoguediagnostic radiopharmaceutical precursor (68Ga-edotreotide PET)
Mechanism of action
After radiolabelling with gallium-68, edotreotide binds somatostatin receptors with high affinity, mainly SSTR2 and to a lesser extent SSTR5, enabling PET localisation of somatostatin-receptor-expressing lesions.
Indications / reported uses
  • Diagnostic PET imaging of somatostatin-receptor overexpression in adults with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours, for localisation of primary tumours and metastases; edotreotide kit requires radiolabelling before administration

Sources: UK SmPC — SomaKit TOC · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Edotreotide Environmental Risk Assessment (ERA) (the Edotreotide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.